Info

Mastering Money

Mastering Money is hosted by Certified Income Specialistâ„¢ Steve Jurich. Steve's comments have been seen on MarketWatch, CNBC.com, Bloomberg, and TheStreet.com. Steve is joined on most days by Money Radio favorite Sinclair Noe as well as experts and authors from the world of Wall Street and real estate. New episodes published every weekday at 9am PST. Listen every weekday to get a handle on emerging market trends, asset allocation strategies, social security, medicare, RMD planning, tax strategies, estate planning, annuities, life insurance and more!
RSS Feed Subscribe in Apple Podcasts Android App iOS App
2018
April
March
February
January


2017
December
November
October
September
August
July
June
May
April
March
February
January


2016
December
November
October
September
August
July
June
May
April
March
February
January


2015
December
November
October
September
August
July
June
May
April
March
February


Categories

All Episodes
Archives
Categories
Now displaying: Page 1

Jun 22, 2015

Big pharma is making a comeback with cutting edge new drugs to do battle with alzheimers, diabetes, various forms of vaccines, oncology, and acute hospital care. Meanwhile,  the Food and Drug Administration has speeded approval of drugs. The agency approved 41 new drugs last year, the most in 18 years, and well above the average of 25 per year since 2005. 

Earlier this year Merck lost its remaining patent protection on Remicade, an arthritis drug and its third biggest seller. By 2017, it will lose protection on the cholesterol drugs Zetia, its No. 2 seller, and Vytorin. In total, about $9.5 billion, or 22% of the company’s $42 billion in 2014 revenue, could be in jeopardy through 2017. However, it has developed new drugs that could be blockbusters. Sinclair and Steve review some fascinating stats on pharmaceutical breakthroughs. Jordan Goodman, author of Barron's financial dictionary and formerly with Money Magazine, joins the A Team for a spirited Q & A.